<DOC>
	<DOCNO>NCT02249988</DOCNO>
	<brief_summary>The study open-label , randomize , comparative , multicenter clinical trial . The purpose study assess efficacy ABX203 , new chronic hepatitis B therapeutic vaccine administer adjunct therapy nucleos ( ) ide analog ( NUCs ) , maintain control Hepatitis B disease cessation treatment NUCs subject HBeAg negative chronic Hepatitis B .</brief_summary>
	<brief_title>Clinical Efficacy ABX203 Therapeutic Vaccine HBeAg Negative Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject 18 65 year age time randomization . Must HBeAg negative antiHBe Abs positive least 1 year prior screen screen . Has HBV DNA &lt; 40 IU/mL least 1 year prior screen screening Has ALT AST level ≤ ULN least 1 year prior screen screen . Must HBsAg positive screening . Has treat NUCs least 2 year prior screen . Has treat PEGIFN IFN least 1 year prior screening . For female , must negative serum pregnancy test screening . For female childbearing potential , must use adequate contraception must agree continue use study period 6 month completion study product administration . Has provide write informed consent . Has elevate blood level alphafetoprotein ( AFP ) ( &gt; 500 ng/mL ) . Has cirrhosis , define platelet count &lt; 150,000/mm3 , esophageal varix image spleen size &gt; 12 , liver stiffness 11 kilopascal [ kPa ] measure elastography use FibroScan® .an AST Platelet Ratio Index ( APRI ) &gt; 2 ) . Has hepatocellular carcinoma ( HCC ) ( diagnose ultrasonography ) . Has liver decompensation ( albumin &lt; 3.5 g/dL bilirubin ≥1.3 mg/dL ) . Is Hepatitis C virus ( HCV ) Ab positive screening . Is Hepatitis delta virus ( HDV ) Ab positive screening . Is Human Immunodeficiency Virus ( HIV ) Ab positive screening . Has immune suppressive disorder treatment immunosuppressive drug . Has treat corticosteroid within 12 week prior first administration study product , exception topical inhale corticosteroid . Has treat rituximab . Has hepatic disease different etiology ( autoimmune hepatitis , toxic hepatitis , Wilson disease , alcoholic hemochromatosis ) . Has history allergic disease reaction likely exacerbate component study product . Has history substance abuse ( drug alcohol ) problem within previous 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>